This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Strong Buy Growth Stocks for this Secular Bull Rally
by Tracey Ryniec
How can the stock market be near another all-time high with a pandemic and 40 million unemployed? Secular bull markets don't care about headlines.
Zacks.com featured highlights include: Vertex Pharmaceuticals, Dollar General, CVS Health and Tractor Supply
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, Dollar General, CVS Health and Tractor Supply
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
by Sumit Singh
Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Why Is Vertex (VRTX) Up 10.4% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
by Zacks Equity Research
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
VRTX vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. ILMN: Which Stock Is the Better Value Option?
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Profit From 5 Stocks Likely to Beat on Earnings
by Sanghamitra Saha
Bet on five stocks that are likely to outdo earnings estimates.
S&P Reclaims 3,000: Buy 6 Stocks With More Than 25% Growth
by Sweta Killa
In the latest market rally driven by hopes surrounding potential coronavirus vaccines and reopening of the economy, the S&P 500 reclaimed its 3,000 level and is poised to rise further.
2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks
by Tirthankar Chakraborty
As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
The Zacks Analyst Blog Highlights: Chegg, Quidel, MarketAxess, Dropbox and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chegg, Quidel, MarketAxess, Dropbox and Vertex Pharmaceuticals
The Zacks Analyst Blog Highlights: Chegg, Nautilus Group, Sprouts Farmers Market, VeriSign and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chegg, Nautilus Group, Sprouts Farmers Market, VeriSign and Vertex Pharmaceuticals
The Zacks Analyst Blog Highlights: The Hain Celestial Group, Murphy USA, Vertex Pharmaceuticals, Sprouts Farmers Market and ASE Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: The Hain Celestial Group, Murphy USA, Vertex Pharmaceuticals, Sprouts Farmers Market and ASE Technology
Vertex Pharmaceuticals, Align Technology, Walmart, Home Depot and Target highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vertex Pharmaceuticals, Align Technology, Walmart, Home Depot and Target highlighted as Zacks Bull and Bear of the Day
5 Reasons Why Growth Stocks Will Soar Further
by Sanghamitra Saha
A few positive developments on the vaccine front, unprecedented economic help, reopening of economies and some bullish economic datapoints should facilitate growth stocks ahead.
Major Indexes Defying "Sell in May" Adage: 5 Growth Picks
by Nalak Das
Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."
Bull of the Day: Vertex Pharma (VRTX)
by Kevin Cook
While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth
Surging Earnings Estimates Signal Good News for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Wall Street to Rally as Powell Talks Recovery: 5 Big Winners
by Tirthankar Chakraborty
Wall Street poised to gain after Powell expressed confidence that the U.S. economy will recover beginning summer.
Buy These 4 Stocks With Attractive Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
3 Reasons Growth Investors Will Love Vertex (VRTX)
by Zacks Equity Research
Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Wall Street Resilient to Crisis-Era Jobless Rate: 5 Picks
by Tirthankar Chakraborty
Stocks finished last week in the green despite massive job losses as the market expects a sharp but short recession.